Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma

Karen Juul Mylam; Anne Lerberg Nielsen; Lars Møller Pedersen; Martin Hutchings

doi:10.1016/j.cpet.2014.06.001

Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma

Karen Juul Mylam, Anne Lerberg Nielsen, Lars Møller Pedersen, Martin Hutchings

4 Citations (Scopus)

Abstract

Diffuse large B-cell lymphoma (DLBCL) is an aggressive and potentially curable type of lymphoma. Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is part of clinical routine for DLBCL in most hospitals and also recommended for staging and end-of-therapy evaluation. FDG-PET/computed tomography (CT) is able to identify nodal and extranodal sites with greater accuracy than CT alone. Little evidence supports the use of surveillance FDG-PET imaging in the follow-up setting because of high rates of false-positive scans and because most studies are retrospective. This article discusses FDG-PET assessment methods and the clinical application of FDG-PET for management of DLBCL.

Original language	English
Journal	P E T Clinics
Volume	9
Issue number	4
Pages (from-to)	443-55, vi
ISSN	1556-8598
DOIs	https://doi.org/10.1016/j.cpet.2014.06.001
Publication status	Published - Oct 2014

Access to Document

10.1016/j.cpet.2014.06.001

Cite this

@article{9a99b168ac3f4a7fa30bab2839d3c994,

title = "Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma",

abstract = "Diffuse large B-cell lymphoma (DLBCL) is an aggressive and potentially curable type of lymphoma. Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is part of clinical routine for DLBCL in most hospitals and also recommended for staging and end-of-therapy evaluation. FDG-PET/computed tomography (CT) is able to identify nodal and extranodal sites with greater accuracy than CT alone. Little evidence supports the use of surveillance FDG-PET imaging in the follow-up setting because of high rates of false-positive scans and because most studies are retrospective. This article discusses FDG-PET assessment methods and the clinical application of FDG-PET for management of DLBCL.",

author = "Mylam, \{Karen Juul\} and Nielsen, \{Anne Lerberg\} and Pedersen, \{Lars M{\o}ller\} and Martin Hutchings",

year = "2014",

month = oct,

doi = "10.1016/j.cpet.2014.06.001",

language = "English",

volume = "9",

pages = "443--55, vi",

journal = "P E T Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders",

number = "4",

}

TY - JOUR

T1 - Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma

AU - Mylam, Karen Juul

AU - Nielsen, Anne Lerberg

AU - Pedersen, Lars Møller

AU - Hutchings, Martin

PY - 2014/10

Y1 - 2014/10

N2 - Diffuse large B-cell lymphoma (DLBCL) is an aggressive and potentially curable type of lymphoma. Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is part of clinical routine for DLBCL in most hospitals and also recommended for staging and end-of-therapy evaluation. FDG-PET/computed tomography (CT) is able to identify nodal and extranodal sites with greater accuracy than CT alone. Little evidence supports the use of surveillance FDG-PET imaging in the follow-up setting because of high rates of false-positive scans and because most studies are retrospective. This article discusses FDG-PET assessment methods and the clinical application of FDG-PET for management of DLBCL.

AB - Diffuse large B-cell lymphoma (DLBCL) is an aggressive and potentially curable type of lymphoma. Fluorine-18-fluorodeoxyglucose positron emission tomography (FDG-PET) is part of clinical routine for DLBCL in most hospitals and also recommended for staging and end-of-therapy evaluation. FDG-PET/computed tomography (CT) is able to identify nodal and extranodal sites with greater accuracy than CT alone. Little evidence supports the use of surveillance FDG-PET imaging in the follow-up setting because of high rates of false-positive scans and because most studies are retrospective. This article discusses FDG-PET assessment methods and the clinical application of FDG-PET for management of DLBCL.

UR - https://www.scopus.com/pages/publications/84907576906

U2 - 10.1016/j.cpet.2014.06.001

DO - 10.1016/j.cpet.2014.06.001

M3 - Journal article

C2 - 26050946

SN - 1556-8598

VL - 9

SP - 443-55, vi

JO - P E T Clinics

JF - P E T Clinics

IS - 4

ER -

Fluorine-18-fluorodeoxyglucose Positron Emission Tomography in Diffuse Large B-cell Lymphoma

Abstract

Access to Document

Other files and links

Fingerprint

Cite this